[
    "{\"step_by_step_thinking\": \"Based on the provided documents, there is no evidence to suggest that Axitinib prolongs survival of pancreatic cancer patients. Document [0] mentions that Phase III clinical trials of Axitinib in combination with gemcitabine showed no evidence of improved survival rates over treatments using gemcitabine alone for advanced pancreatic cancer. Document [1] also states that Axitinib/gemcitabine did not provide a survival benefit over gemcitabine alone in patients with advanced pancreatic cancer. Therefore, the answer is B. no.\", \"answer_choice\": \"B\"}"
]